Diffuse large B-cell Lymphoma
Conditions
Interventions
Research group:Study combined miniCHOP after induction of OR Orelabrutinib 150mg QD d1-21, Ruximab 375mg / m2 d1)
Sponsors
The First Affiliated Hospital of Zhejiang University Medical College
Eligibility
Sex/Gender
All
Age
65 Years to 120 Years
Inclusion criteria
Inclusion criteria: 1.Initial-treatment DLBCL was confirmed based on histopathology, and the immunohistochemical examination was positive for CD20. 2.Human subtype by pathological immunohistochemistry. 3.At least one radiologically measurable lesion was present. 4.Age was 65 years old at the time of enrollment. 5.Informed consent was obtained from the patient or family members.
Exclusion criteria
Exclusion criteria: 1.Pregnancy, lactating women, and patients of childbearing age who are reluctant to use contraception. 2.Abnormal liver function (1.5 times total bilirubin> the upper limit of normal, ALT / AST> 2.5 times normal ALT / AST> 5 times normal ALT / AST), abnormal renal function (1.5 times the upper limit of serum creatinine> normal). 3.Neutrophil absolute count 1x103 copies / ml), untreated syphilis positive, and patients with active TB. 9.Previous history of lymphoma, considered in a patient with Richter's syndrome. 10.Other investigator judged ineligible for this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| complete remission rate (CRR) ; | — |
Secondary
| Measure | Time frame |
|---|---|
| progression-free survival(PFS);Event-free survival(EFS);Overall response rate(ORR); | — |
Countries
China
Contacts
Public ContactWazhou Xie
The First Affiliated Hospital of Zhejiang University Medical College
Outcome results
None listed